All In Biotech

Free tool

FAERS Monitor: Nexlizet

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 211617 or its brand name (Nexlizet, Bempedoic Acid, Ezetimibe). Reports on generic versions are filed under their own applications.

Reports

719

Serious

155

22% of reports

Hospitalization

62

Death reported

5

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • myalgia62
  • arthralgia60
  • pain in extremity47
  • fatigue38
  • muscle spasms36
  • headache31
  • back pain30
  • diarrhoea29
  • pain27
  • dizziness26
  • product dose omission issue26
  • drug ineffective24
  • rash24
  • abdominal pain upper22
  • dyspnoea20

Reports by year received

View as table
YearReports
20181
202042
2021135
202293
202341
202493
2025171
2026143

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,440 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
myalgiaSignal6210.78.4538
muscle spasmsSignal365.74.2137
pain in extremitySignal474.73.5134
arthralgiaSignal604.23.3147
back painSignal303.82.759
abdominal pain upperSignal223.12.130
product dose omission issueSignal262.61.824
rash241.61.15
dizziness261.51.04
headache311.41.04
fatigue381.41.05
diarrhoea291.30.92
pain271.30.91
dyspnoea201.00.70
drug ineffective240.50.410

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.